EKE. A. Kovalev

E. A. Kovalev

*This is an algorithmically generated author record based on publicly available information.

E. A. Kovalev has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The impact of clinical decision support systems on adherence to clinical guidelines and achieving target levels of low-density lipoprotein cholesterol in patients at risk of developing cardiovascular events (SuccESS)

    by K. S. Astrakova (Benimetskaya), I. L. Mikheenko, A. E. Uranov, A. A. Gartung, E. A. Kovalev, A. A. Spiridonov, I. I. Shestova, I. L. Strokolskaya, M. A. Meshkova, L. I. Esev, et al.

    Aim. To assess the effectiveness of clinical decision support system (CDSS) implementation strategy in increasing the frequency of low-density lipoprotein cholesterol (LDL-С) monitoring in patients hospitalized for acute cardiovascular events (CVEs), in patients with coronary artery disease (CAD) or dyslipidemia.Material and methods. A non-interventional, retrospective, multicentre study assessing the impact of a CDSS with automatic electronic medical record (EMR) data processing on adherence to guidelines in patients at risk of cardiovascular diseases (SuccESS) was performed. The study included two cohorts of patients from healthcare facilities in three regions of Russia. The main cohort consisted of patients hospitalized for acute CVEs, with 12,227 patients included in the first follow-up period and 11,364 patients included in the second follow-up period. The additional cohort consisted of patients with stable CAD or dyslipidemia, with 54 469 patients included in the first follow-up period and 94,616 patients included in the second follow-up period. The study assessed follow-up findings in real-world clinical practice before and after the CDSS was implemented (first and second follow-up periods, respectively). The median duration of follow-up in the main cohort was >158 days in the first follow-up period and >227 days in the second follow-up period.Results. In the second follow-up period the proportion of patients with available data on LDL-C control in the EMR increased from 12.3% to 18.8% (here and further — relative change: +52.3%, pConclusion. The study findings demonstrate the positive impact of CDSS on several parameters that determine the quality and organization of medical care. The CDSS can be used to improve clinical and managerial decisions.


  • Personalized approach to treatment choice using a digital profile of patient with cardiovascular diseases: the features of clinical decision-making support service

    by A.M. Shangina, K.S. Benimetskaya, Yu.E. Efremova, A.E. Uranov, E.A. Kovalev, I.L. Mikheenko, D.V. Losik, S.A. Boytsov

    Digital transformation of healthcare systems including artificial intelligence (AI) technologies and clinical decision-making support systems (CDSS) became popular worldwide. There is a growing need for early diagnosis and treatment of cardiovascular diseases with personalized approach to these issues. We reviewed appropriate foreign and domestic digital solutions in clinical practice. CDSS is valuable for physicians to receive a digitalized cardiovascular status and “hints” about the patient’s risks, examination and treatment in accordance with clinical guidelines considering absolute and relative contraindications, as well as AI-predicted missing important parameters. The doctor is able to choose the most effective and safe drug considering clinical trials and network meta-analysis in CDSS functionality. CDSS analytical dashboards allow the attending physician and healthcare organizer to automate dispensary follow-up by selecting patients with unmet health targets and assess the quality of care. CDSS-based automatic assessment of indications for drugs according to clinical recommendations allows planning preferential drug provision. CDSS has a potential to improve physician adherence to clinical guidelines and facilitate selection of personalized therapy for patients with cardiovascular diseases.


  • Open Access

    Retrospective Analysis of Lipid-Lowering and Antiplatelet Therapy Regimen by Clinical Decision Support Service Based on Real-World Data from Electronic Medical Records “Intellect 3 Study”

    by K. S. Benimetskaya, S. I. Provatorov, M. V. Ezhov, Y. S. Krivosheev, A. D. Gavrilko, A. E. Uranov, I. L. Mikheenko, E. A. Kovalev, A. V. Ponomarenko, A. M. Shangina, et al.

    Aim To evaluate prescription of lipid-lowering and antithrombotic therapy in clinical practice and to compare differences in recommendations using the clinical decision support service (CDSS). Material and methods Electronic medical records (EMR) of 300 patients from the Chazov National Medical Research Center of Cardiology, as well as from medical organizations controlled by the Department of Health of the Lipetsk Region and the Ministry of Health of the Voronezh Region, were analyzed for the period of August - December 2022, during the pilot implementation of CDSS. Retrospective information about the prescription of lipid-lowering and antithrombotic therapy from the EMR was compared with the CDSS guidelines under the expert supervision based on digitized clinical and laboratory profiles of patients. The study primary endpoint was a change in the initially prescribed lipid-lowering and / or antithrombotic therapy as per CDSS guidelines. Results Overall 292 patients were included in the final analysis; 46 (15.7 %) were from the primary prevention group and 246 (84.3 %) from the secondary prevention group. In group 1, the lipid-lowering therapy recommended by the CDSS differed by 50 % (pConclusion The use of CDSS may improve the practice of choosing lipid-lowering and antithrombotic therapy for prevention of cardiovascular complications.